Screener
AnaptysBio, Inc. ANAB Biopharma Company — Net Income Loss
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other expense, net | (18,207) | (11,746) |
| Loss before income taxes | (52,844) | (39,285) |
| Provision for income taxes | (40) | (44) |
| Net loss | (52,884) | (39,329) |
| Other comprehensive loss: | ||
| Unrealized loss on available-for-sale securities | (122) | (144) |
| Comprehensive loss | $(53,006) | $(39,473) |
| Net loss per common share: |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s biopharma company — net income loss?
- AnaptysBio, Inc. (ANAB) reported biopharma company — net income loss of -$50.48M in Q1 2026.
- How has AnaptysBio, Inc.'s biopharma company — net income loss changed year-over-year?
- AnaptysBio, Inc.'s biopharma company — net income loss decreased by 7.0% year-over-year, from -$47.2M to -$50.48M.
- What does biopharma company — net income loss mean?
- This metric represents the bottom-line financial result for the biopharma business segment, calculated as total revenues minus all operating and non-operating expenses. It serves as the primary indicator of the segment's overall profitability or burn rate. For early-stage biotechnology firms, this figure is typically negative as capital is prioritized for clinical development.
Ask your AI about AnaptysBio, Inc.'s biopharma company — net income loss.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude